New Launch2 Sept 2025, 10:34 am
Glenmark Pharmaceuticals Inc., USA to Launch Eribulin Mesylate Injection, Expected to Achieve Annual Sales of $66.3 Million
AI Summary
Glenmark Pharmaceuticals Inc., USA is set to launch Eribulin Mesylate Injection, 1mg/2MI (0.5 mg/mL) Single-Dose Vials in September 2025. The drug is bioequivalent and therapeutically equivalent to Halaven® Injection, 1 mg/2 mL (0.5 mg/mL), of Eisai, Inc. According to IQVIA® sales data for the 12-month period ending July 2025, the Halaven® Injection market achieved annual sales of approximately $66.3 million. The launch marks Glenmark's commitment to growing its portfolio of products within the institutional channel and reinforces its dedication to bring quality and affordable alternatives to market for patients in need.
Key Highlights
- Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2MI (0.5 mg/mL) Single-Dose Vials in September 2025.
- The drug is bioequivalent and therapeutically equivalent to Halaven® Injection, 1 mg/2 mL (0.5 mg/mL), of Eisai, Inc.
- According to IQVIA® sales data, the Halaven® Injection market achieved annual sales of approximately $66.3 million for the 12-month period ending July 2025.
- The launch marks Glenmark's commitment to growing its portfolio of products within the institutional channel.
- The launch reinforces Glenmark's dedication to bring quality and affordable alternatives to market for patients in need.